Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02125084
Title Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate Cancer
Recruitment Completed
Gender male
Phase Phase I
Variant Requirements No
Sponsors SCRI Development Innovations, LLC

prostate adenocarcinoma


Enzalutamide + Everolimus

Age Groups: adult
Covered Countries USA

No variant requirements are available.